GlassScriptPhysician profile
Dilip J Karnik
NPI 1407808900
$1,285.02
in general payments reported to CMS, 2019-2025
20 companies · $21.41 in 2025
The $21.41 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $226 · 2021: $11.40 · 2022: $15.62 · 2023: $9.92 · 2025: $21.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $31.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $31.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $273.07 | 2019-2020 | |
| Greenwich Biosciences, INC. | $227.05 | 2019-2020 | |
| Neos Therapeutics, LP | $135.54 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $84.38 | 2019 | |
| Tris Pharma INC | $73.84 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $68.85 | 2019-2020 | |
| Shire North American Group INC | $56.06 | 2019 | |
| Travere Therapeutics, INC. | $55.26 | 2019-2023 | Cholbam |
| Takeda Pharmaceuticals U.S.A., INC. | $53.29 | 2019 | |
| Supernus Pharmaceuticals, INC. | $45.25 | 2019-2021 | |
| Ucb, INC. | $43.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.53 | 2019-2020 | |
| Saol Therapeutics INC. | $25.98 | 2019 | |
| Intrabio INC | $21.41 | 2025 | Aqneursa |
| Biogen, INC. | $17.40 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $14.65 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $13.53 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $12.32 | 2019 | |
| Adlon Therapeutics L.P. | $11.17 | 2019 | |
| Eisai INC. | $10.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dilip Karnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.